{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T03:06:06Z","timestamp":1777345566212,"version":"3.51.4"},"reference-count":60,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1016\/j.jaci.2005.11.002","type":"journal-article","created":{"date-parts":[[2006,2,8]],"date-time":"2006-02-08T13:25:05Z","timestamp":1139405105000},"page":"S464-S470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"S2","title":["8. Drug allergy"],"prefix":"10.1016","volume":"117","author":[{"given":"Paul A.","family":"Greenberger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2005.11.002_bib1","series-title":"Drug allergy and protocols for management of drug allergies","author":"Grammer","year":"2003"},{"key":"10.1016\/j.jaci.2005.11.002_bib2","series-title":"Patterson's allergic diseases","first-page":"295","article-title":"Drug allergy part A: introduction, epidemiology, classification of adverse reactions, immunological basis, risk factors, evaluation of patients with suspected drug allergy, patient management considerations","author":"Ditto","year":"2002"},{"key":"10.1016\/j.jaci.2005.11.002_bib3","doi-asserted-by":"crossref","first-page":"352","DOI":"10.7326\/0003-4819-142-5-200503010-00010","article-title":"Fumbled handoffs: one dropped ball after another","volume":"142","author":"Gandhi","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaci.2005.11.002_bib4","doi-asserted-by":"crossref","first-page":"756","DOI":"10.7326\/0003-4819-142-9-200505030-00012","article-title":"Five system barriers to achieving ultrasafe health care","volume":"142","author":"Amalberti","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaci.2005.11.002_bib5","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1001\/jama.293.17.2131","article-title":"The Research on Adverse Drug Events and Reports (RADAR) project","volume":"293","author":"Bennett","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2005.11.002_bib6","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1001\/jama.289.9.1107","article-title":"Incidence and preventability of adverse drug events among older persons in the ambulatory setting","volume":"289","author":"Gurwitz","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2005.11.002_bib7","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1056\/NEJMsa020703","article-title":"Adverse drug events in ambulatory care","volume":"348","author":"Gandhi","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2005.11.002_bib8","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1093\/ajhp\/59.18.1742","article-title":"Identifying clinically significant preventable adverse drug events through a hospital's database of adverse drug reaction reports","volume":"59","author":"Wintherstein","year":"2002","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jaci.2005.11.002_bib9","series-title":"To err is human: building a safer health system","year":"2000"},{"key":"10.1016\/j.jaci.2005.11.002_bib10","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00228-004-0830-4","article-title":"The majority of hospitalized patients have drug-related problems: results from a prospective study in general hospitals","volume":"60","author":"Blix","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jaci.2005.11.002_bib11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1081-1206(10)62234-X","article-title":"IgE-mediated anaphylaxis after first intravenous infusion of cyclosporine","volume":"87","author":"Ebo","year":"2001","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2005.11.002_bib12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1081-1206(10)62949-3","article-title":"Anaphylaxis to intravenous cyclosporine and tolerance to oral cyclosporine: case report and review","volume":"80","author":"Volcheck","year":"1998","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2005.11.002_bib13","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1345\/aph.19302","article-title":"Cyclosporine-induced anaphylaxis","volume":"34","author":"Kuiper","year":"2000","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaci.2005.11.002_bib14","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1111\/j.1600-6143.2004.00429.x","article-title":"Sirolimus-induced angioedema","volume":"6","author":"Wadei","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jaci.2005.11.002_bib15","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.amjmed.2004.03.040","article-title":"Adverse effects of thalidomide administration in patients with neoplastic diseases","volume":"117","author":"Dimopoulos","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.jaci.2005.11.002_bib16","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0002-9343(03)00390-5","article-title":"Autoimmune aspects of cytokine and anticytokine therapies","volume":"115","author":"Krause","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/j.jaci.2005.11.002_bib17","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1002\/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D","article-title":"Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials","volume":"43","author":"Charles","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2005.11.002_bib18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jbspin.2004.03.003","article-title":"Autoantibody induction in patients with refractory spondyloarthropathy treated with infliximab and methotrexate","volume":"72","author":"Sellam","year":"2005","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jaci.2005.11.002_bib19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000075046","article-title":"A prospective study of cutaneous adverse events induced by low-dose alpha-interferon treatment for malignant melanoma","volume":"208","author":"Guillot","year":"2004","journal-title":"Dermatology"},{"key":"10.1016\/j.jaci.2005.11.002_bib20","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","article-title":"Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8)","volume":"94","author":"Winkler","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2005.11.002_bib21","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1056\/NEJMoa012864","article-title":"Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus","volume":"346","author":"Herold","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2005.11.002_bib22","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1046\/j.1399-0012.2003.00102.x","article-title":"Induction therapy by anti-thymocyte globulin (rabbit) in renal transplantation: a 1-yr follow-up of safety and efficacy","volume":"17","author":"Buchler","year":"2003","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jaci.2005.11.002_bib23","first-page":"180","article-title":"IgE against human (recombinant DNA) insulin in patients with systemic insulin allergy","volume":"73","author":"Grammer","year":"1984","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2005.11.002_bib24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0091-6749(81)90180-9","article-title":"Skin testing to detect penicillin allergy","volume":"68","author":"Sullivan","year":"1981","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2005.11.002_bib25","first-page":"303A","article-title":"Patterns of anti-penicillin IgE antibodies in 634 penicillin allergic patients","volume":"49","author":"Greenberger","year":"2001","journal-title":"J Invest Med"},{"key":"10.1016\/j.jaci.2005.11.002_bib26","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/archinte.1992.00400170105020","article-title":"Results of the National Institute of Allergy and Infectious Diseases collaborative clinical trial to test the predictive value of skin testing with major and minor penicillin derivatives in hospitalized adults","volume":"152","author":"Sogn","year":"1992","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jaci.2005.11.002_bib27","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S1081-1206(10)62466-0","article-title":"Penicillin allergy: prevalence of vague history in skin test-positive patients","volume":"85","author":"Solensky","year":"2000","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2005.11.002_bib28","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1067\/mai.2003.1385","article-title":"Penicillin skin testing in advance of need: multiyear follow-up in 568 test result-negative subjects exposed to oral penicillins","volume":"111","author":"Macy","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2005.11.002_bib29","first-page":"161","article-title":"Incidence of resensitization after tolerating penicillin treatment in penicillin-allergic patients","volume":"25","author":"Bittner","year":"2004","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaci.2005.11.002_bib30","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra993637","article-title":"Cephalosporin allergy","volume":"345","author":"Kelkar","year":"2001","journal-title":"N Engl J Med"},{"issue":"suppl","key":"10.1016\/j.jaci.2005.11.002_bib31","doi-asserted-by":"crossref","first-page":"S182","DOI":"10.1016\/j.jaci.2004.12.740","article-title":"Utility of penicillin major and minor determinants for identification of allergic reactions to cephalosporins","volume":"115","author":"Greenberger","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2005.11.002_bib32","doi-asserted-by":"crossref","first-page":"16","DOI":"10.7326\/0003-4819-141-1-200407060-00010","article-title":"Cross-reactivity and tolerability of cephalosporins in patients with immediate hypersensitivity to penicillins","volume":"141","author":"Romano","year":"2004","journal-title":"Ann Intern Med"},{"issue":"suppl","key":"10.1016\/j.jaci.2005.11.002_bib33","doi-asserted-by":"crossref","first-page":"S548","DOI":"10.1067\/mai.2003.93","article-title":"Drug allergy","volume":"111","author":"Gruchalla","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2005.11.002_bib34","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/0003-4819-105-2-179","article-title":"Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity","volume":"105","author":"Shear","year":"1986","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaci.2005.11.002_bib35","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa022963","article-title":"Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics","volume":"349","author":"Strom","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2005.11.002_bib36","series-title":"Patterson's allergic diseases","first-page":"335","article-title":"Drug allergy part B: allergic reactions to individual drugs: low molecular weight","author":"Greenberger","year":"2002"},{"key":"10.1016\/j.jaci.2005.11.002_bib37","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1001\/jama.292.24.3017","article-title":"Aspirin sensitivity: implications for patients with coronary artery disease","volume":"292","author":"Gollapudi","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2005.11.002_bib38","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0091-6749(62)80451-5","article-title":"Aspirin in chronic urticaria and\/or angioedema: studies of sensitivity and desensitization","volume":"69","author":"Mathison","year":"1982","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2005.11.002_bib39","first-page":"366","article-title":"Clinical characteristics of childhood erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in Taiwanese children","volume":"37","author":"Lam","year":"2004","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jaci.2005.11.002_bib40","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/S0140-6736(98)05418-X","article-title":"Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of epileptic therapy: a case-control study","volume":"353","author":"Rzany","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2005.11.002_bib41","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaci.2004.07.047","article-title":"Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells","volume":"114","author":"Nassif","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2005.11.002_bib42","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jaci.2005.11.002_bib43","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S0002-9440(10)64284-8","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand","volume":"162","author":"Abe","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaci.2005.11.002_bib44","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.139.1.33","article-title":"Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"139","author":"Bachot","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaci.2005.11.002_bib45","first-page":"339","article-title":"DRESS syndrome associated with carbamazepine and phenytoin","volume":"14","author":"Allam","year":"2004","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaci.2005.11.002_bib46","series-title":"Patterson's allergic diseases","first-page":"289","article-title":"Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis","author":"Tripathi","year":"2002"},{"key":"10.1016\/j.jaci.2005.11.002_bib47","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2500\/108854100778250914","article-title":"Corticosteroid therapy in an additional 13 cases of Stevens-Johnson syndrome: a total series of 67 cases","volume":"21","author":"Tripathi","year":"2000","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaci.2005.11.002_bib48","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0021-8707(69)90066-5","article-title":"Prediction of penicillin allergy by immunological tests","volume":"43","author":"Levine","year":"1969","journal-title":"J Allergy"},{"key":"10.1016\/j.jaci.2005.11.002_bib49","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0091-6749(88)91001-9","article-title":"Imipenem cross-reactivity with penicillin in humans","volume":"82","author":"Saxon","year":"1988","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2005.11.002_bib50","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1093\/ajhp\/54.22.2616","article-title":"Anticonvulsant cross-sensitivity","volume":"54","author":"Canaday","year":"1997","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jaci.2005.11.002_bib51","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1001\/jama.1997.03550030072037","article-title":"Recurrent angiotensin-converting enzyme inhibitor-associated angioedema","volume":"278","author":"Brown","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2005.11.002_bib52","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.1988.03410070095035","article-title":"Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition","volume":"260","author":"Slater","year":"1988","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2005.11.002_bib53","doi-asserted-by":"crossref","first-page":"975","DOI":"10.7326\/0003-4819-68-5-975","article-title":"Intolerance to aspirin. Clinical studies and consideration of its pathogenesis","volume":"68","author":"Samter","year":"1968","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaci.2005.11.002_bib54","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJM197107012850104","article-title":"Routine use of penicillin skin testing on an inpatient service","volume":"285","author":"Adkinson","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2005.11.002_bib55","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1067\/mai.2001.116290","article-title":"Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma","volume":"108","author":"Stevenson","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2005.11.002_bib56","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1046\/j.1365-2222.2001.01075.x","article-title":"Safety of a specific COX-2 inhibitor in aspirin-induced asthma","volume":"31","author":"Szczeklik","year":"2001","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2005.11.002_bib57","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1081-1206(10)61392-0","article-title":"Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease","volume":"93","author":"Woessner","year":"2004","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2005.11.002_bib58","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S1081-1206(10)61395-6","article-title":"Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs","volume":"93","author":"Quiralte","year":"2004","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2005.11.002_bib59","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1001\/archinte.164.8.910","article-title":"Angioedema associated with angiotensin-converting enzyme inhibitor use","volume":"164","author":"Cicardi","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jaci.2005.11.002_bib60","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/0091-6749(91)90135-B","article-title":"The prevention of immediate generalized reactions to radiocontrast media in high risk patients","volume":"87","author":"Greenberger","year":"1991","journal-title":"J Allergy Clin Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674905025042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674905025042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T05:02:52Z","timestamp":1758776572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674905025042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["S0091674905025042"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2005.11.002","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2006,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"8. Drug allergy","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2005.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 American Academy of Allergy, Asthma and Immunology. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}